Therapy-related peripheral neuropathy in multiple myeloma patients

Hematological Oncology

Volumn 33, Issue 4, 2015, Pages 113-119

  Morawska, Marta ^a   Grzasko, Norbert ^a   Kostyra, Magdalena ^b   Wojciechowicz, Jolanta ^b   Hus, Marek ^a  

^a SPSK1   (Poland)

^b SPSK1   (Poland)

Author keywords

Bendamustine; BiPN; Multiple myeloma; Peripheral neuropathy; Polyneuropathy; TiPM

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; BENDAMUSTINE; BORTEZOMIB; CARBAMAZEPINE; DEXAMETHASONE; DULOXETINE; GABAPENTIN; GLUTAMINE; KETAMINE; LENALIDOMIDE; LEVACECARNINE; MELPHALAN; MORPHINE; NORTRIPTYLINE; OXYCODONE; PREDNISONE; PREGABALIN; THALIDOMIDE; THIOCTIC ACID; TRAMADOL; TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE;

ANALGESIA; CALCIUM HOMEOSTASIS; CANCER CHEMOTHERAPY; CELL SURVIVAL; CLINICAL FEATURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EXPOSURE; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE MYELOMA; NEUROTOXICITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; CHEMICALLY INDUCED; COMPLICATION; FEMALE; MALE; RISK FACTOR;

FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 84955203330     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2149     Document Type: Review

References (50)

1. Sonneveld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc Hematol Educ Program 2010: 2010, 423-430.
2. Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010; 11: 1086-1095.
3. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007; 69: 573-581.
4. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27: 3518-3525.
5. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 2005; 18: 673-688.
6. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338: 1601-1607.
7. Tariman JD, Love G, McCullagh E, Sandifer S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008; 12: 29-36.
8. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006; 33: 15-49.
9. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1year) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005; 74: 212-216.
10. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110: 1042-1049.
11. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008; 13: 275-282.
12. Malhotra P, Choudhary PP, Lal V, Varma N, Suri V, Varma S. Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis. Leuk Lymphoma 2011; 52: 2135-2138.
13. Walsh JC. The neuropathy of multiple myeloma: an electrophysiological and histological study. Arch Neurol 1971; 25: 404-414.
14. San Miguel JF, Schlag R, Khuageva NK, et al. VISTA trial investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
15. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-3120.
16. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose modification guideline. Br J Haematol 2009; 144: 895-903.
17. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010; 95: 311-319.
18. Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003; 60: 877-878.
19. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507-4514.
20. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons- O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59: 1872-1875.
21. Coutsouvelis J, Corallo CE. Thalidomide-induced bradycardia and its management. Med J Aust 2004; 180: 366-367.
22. Dimopoulos M, Spencer A, Attal M, et al. Multiple myeloma (010) study investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
23. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593-1599.
24. Cancer Therapy Evaluation Program, Common Terminology Criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS http://ctep.cancer.gov [accessed 9 August 2006].
25. Antoine J-C, Camdessanche J-P. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007; 6: 75-86.
26. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13: 27-46.
27. Fernyhough P, Smith DR, Schapansky J, et al. Activation of nuclear factor-kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. J Neurosci 2005; 25: 1682-1690.
28. Schwartzman RJ, Chevlen E, Bengtson K. Thalidomide has activity in treating complex regional pain syndrome (multiple letters). Arch Intern Med 2003; 163: 1487-1488.
29. Bennett GJ, Paice JA. Peripheral neuropathy: experimental findings, clinical approaches. J Support Oncol 2007; 5: 61-63.
30. Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008; 7: 940-949.
31. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
32. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584-593.
33. von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008; 81: 247-252.
34. Jagganath S, Hofmeister C, Siegel D, et al. Pomalidomide with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide and bortezomib: updated phase 2 results and age subgroup analysis. 54th ASH Annual Meeting and Exposition, Atlanta GA, 8-11 December 2012.
35. Leleu X, Attal M, Moreau P, et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02. 52nd ASH Annual Meeting and Exposition, Orlando FL, 4-7 December 2010.
36. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
37. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
38. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498-1505.
39. Anderson KC, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study [abstract]. J Clin Oncol 2009; 27: 8536a.
40. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide andhematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
41. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27: 1492-1501.
42. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 2011; 71: 625-649.
43. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-317.
44. Hoy SM. Bendamustine. A review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma. Drugs 2012; 72: 1929-1950.
45. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26: 595-608.
46. Velasco R, Petit J, Clapes V, Verdu E, Navarro X, Bruna J. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010; 15: 7-25.
47. Halat KM, Dennehy CE. Botanicals and dietary supplements in diabetic peripheral neuropathy. J Am Board Fam Pract 2003; 16: 4757.
48. Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002; 20: 3359-3361.
49. Bird JM, Owen RG, D'Sa S, et al. Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154: 32-75.
50. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-251.